Preclinical and clinical results with the natural marine product ET-743

Author： D’Incalci Maurizio   Jimeno José  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.11, 2003-11, pp. : 1843-1853

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ET-743

By Cvetkovic R.S.   Figgitt D.P.   Plosker G.L.  

Drugs, Vol. 62, Iss. 8, 2002-01 ,pp. : 1185-1192

Adis International

Access to resources Recommend Favorite

Advanced Preclinical and Clinical Trials of Natural Products and Related Compounds from Marine Sources

By  

Current Medicinal Chemistry, Vol. 11, Iss. 13, 2004-07 ,pp. : 1693-1713

Bentham Science Publishers

Access to resources Recommend Favorite

Trabectedin: ET 743, Ecteinascidin 743, Yondelis

By  

Drugs in R&D, Vol. 4, Iss. 1, 2003-01 ,pp. : 75-81

Adis International

Access to resources Recommend Favorite

Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766

By Adis International Limited  

Drugs in R&D, Vol. 7, Iss. 5, 2006-01 ,pp. : 317-328

Adis International

Access to resources Recommend Favorite

In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug

By Brandon Esther   Sparidans Rolf   Guijt Kees-Jan   Löwenthal Sjoerd   Meijerman Irma   Beijnen Jos   Schellens Jan  

Investigational New Drugs, Vol. 24, Iss. 1, 2006-01 ,pp. : 3-14

Springer Publishing Company

Access to resources Recommend Favorite